Stability-Indicating Analytical Method Development using Quality by Design (QbD) for Simultaneous Estimation of Ezetimibe and Glimepiride

Introduction

The pharmaceutical industry is increasingly adopting Quality by Design (QbD) principles to ensure the quality and robustness of analytical methods. In the context of combination therapies, such as the fixed-dose combination of Ezetimibe (a lipid-lowering agent) and Glimepiride (an antidiabetic agent), the development of a stability-indicating method (SIM) is critical. A robust SIM ensures that the assay can accurately measure the active ingredients in the presence of their degradation products, impurities, and excipients.

The QbD Paradigm in Analytical Chemistry

QbD shifts analytical method development from a traditional "trial-and-error" approach to a systematic, risk-based methodology. The primary components include:

• Analytical Target Profile (ATP): Defining the criteria for method performance (e.g., precision, accuracy, specificity).
• Critical Quality Attributes (CQAs): Performance indicators like resolution between peaks, retention time, and tailing factors.
• Critical Process Parameters (CPPs): Variables that impact the CQAs, such as mobile phase pH, flow rate, column temperature, and organic modifier concentration.
• Design Space: The multidimensional combination of input variables that provides assurance of quality.

Method Development Strategy

For the simultaneous estimation of Ezetimibe and Glimepiride, High-Performance Liquid Chromatography (HPLC) is the preferred technique. The process begins with Risk Assessment, using tools like Ishikawa (Fishbone) diagrams to identify potential sources of variability.

Experimental Design (DoE)

A fractional factorial or central composite design is typically employed to investigate the interaction between CPPs. By modeling the response surface, researchers can identify the "sweet spot" where both drugs are resolved from forced degradation products (acid, base, peroxide, and thermal stress).

Forced Degradation Studies

To prove the stability-indicating nature of the method, the drug combination must be subjected to various stress conditions:

• Hydrolytic Stress: Exposure to 0.1M HCl and 0.1M NaOH.
• Oxidative Stress: Exposure to 3% H2O2.
• Photolytic Stress: Exposure to UV light.
• Thermal Stress: Elevated temperatures in a dry heat oven.

The validated QbD method must demonstrate that degradation products do not interfere with the quantitative analysis of the parent peaks of Ezetimibe and Glimepiride.

Method Validation

Following the QbD optimization, the method is validated according to ICH Q2(R1) guidelines. Key parameters include:

• Specificity: Resolution between the active drug and the degradation products.
• Linearity: Establishing a reliable calibration curve.
• Accuracy: Percentage recovery at 80%, 100%, and 120% concentration levels.
• Robustness: Demonstrating that small, deliberate changes in method parameters (within the established design space) do not impact the analytical results.

Conclusion

The application of QbD principles to the analytical method development for Ezetimibe and Glimepiride leads to a higher degree of confidence in the method's performance throughout its lifecycle. By understanding the relationship between method inputs and outputs, laboratories can minimize re-validation efforts and ensure consistent quality in the simultaneous determination of these therapeutic agents.